EUVIMEDObjevte EUVIMED
CrossrefInformační karta

Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

Carmen Yagüe Caballero, Santiago García López, Ana Royo Esteban, Laura Figueras Panillo, Pilar Nos, Luisa de Castro, M. Dolores Martín‐Arranz, Manuel Barreiro‐de Acosta, Elena Ricart, Ruth de Francisco, Eva Iglesias, Antonio Giordano, Pilar Varela, Iago Rodríguez‐Lago, Montserrat Rivero, Beatriz Sicilia, Merce Navarro‐Llavat, Isabel Vera, Carles Suria, Jordi Guardiola, Jesús Barrio, Margalida Calafat, Ana Gutiérrez, Xavier Calvet, David Rafael de la Cruz, Francisco Mesonero, Cristina Martínez Pascual, Javier P. Gisbert, Carla J. Gargallo‐Puyuelo, David Monfort i Miquel, Mónica Sierra, Laura Arranz, Cristina Rodríguez‐Gutiérrez, Rufo Lorente, Fernando Bermejo, Lucía Márquez‐Mosquera, Gisela Torres Vicente, José Lázaro Pérez‐Calle, José M. Huguet, Laura Ramos

Alimentary Pharmacology & Therapeutics · 2026-11 · 64 (9) · 1234-1247

DOI: 10.1111/apt.70904 ↗
AbstraktBibliografické údaje

Abstrakt

ABSTRACT Background The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti‐TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti‐TNF treatment in this scenario. Methods Multicentre study based on data from the ENEIDA registry. Patients who received second‐line anti‐TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second‐line anti‐TNF after another anti‐TNF and patients receiving first‐line anti‐TNF therapy. Treatment durability and short‐ and long‐term clinical effectiveness were assessed. Results Sixty‐six Crohn's disease patients and 117 UC patients receiving anti‐TNF after other MOA were included. In CD, second‐line anti‐TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first‐line anti‐TNF therapy (HR 1.55; 95% CI, 1.05–2.30), without significant differences in short‐ or long‐term clinical effectiveness. In UC, anti‐TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first‐line anti‐TNF therapy (HR 1.69; 95% CI, 1.31–2.19) and with anti‐TNF after another anti‐TNF agent (HR 1.91; 95% CI, 1.48–2.48), its remission rates significantly lower at both short‐ and long‐term follow‐up ( p < 0.001). Conclusions Anti‐TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first‐line therapy or after another anti‐TNF agent, especially in UC.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →